We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

65 hedge funds and large institutions have $140M invested in Ocular Therapeutix in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more capital invested

Capital invested by funds: $60.1M → $140M (+$80.1M)

108% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $622K

92% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 13

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

11.91% more ownership

Funds ownership: 45.88% → 57.79% (+12%)

6% less funds holding

Funds holding: 69 → 65 (-4)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
65
Holders Change
-4
Holders Change %
-5.8%
% of All Funds
1.49%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
7
Increased
25
Reduced
13
Closed
11
Calls
$1.29M
Puts
$622K
Net Calls
+$670K
Net Calls Change
+$726K

Top Buyers

Rank Fund Capital Flow
1
SR
Summer Road
Florida
+$17M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$11.7M
3
OM
Opaleye Management
Massachusetts
+$6.25M
4
DAM
Deltec Asset Management
New York
+$2.09M
5
Jennison Associates
Jennison Associates
New York
+$1.68M

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$277K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$267K
3
VF
Virtu Financial
New York
-$241K
4
Wells Fargo
Wells Fargo
California
-$186K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$177K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$21.1M +$11.7M +2,074,949 +178%
SR
2
Summer Road
Florida
$19.7M +$17M +3,027,488 New
Jennison Associates
3
Jennison Associates
New York
$14.9M +$1.68M +297,984 +15%
VVM
4
Versant Venture Management
California
$14.4M – – –
BlackRock
5
BlackRock
New York
$11M +$1.56M +278,035 +20%
SHI
6
SV Health Investors
Massachusetts
$10.4M – – –
Wellington Management Group
7
Wellington Management Group
Massachusetts
$9.44M +$1.14M +202,337 +16%
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.75M +$1.54M +273,677 +26%
OM
9
Opaleye Management
Massachusetts
$7.23M +$6.25M +1,111,000 New
DAM
10
Deltec Asset Management
New York
$3.82M +$2.09M +372,000 +174%
State Street
11
State Street
Massachusetts
$2.44M +$123K +21,782 +6%
Northern Trust
12
Northern Trust
Illinois
$2.11M +$355K +62,993 +24%
Morgan Stanley
13
Morgan Stanley
New York
$1.77M +$74.5K +13,230 +5%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.53M +$329K +58,535 +33%
ACM
15
Atika Capital Management
New York
$1.43M +$1.24M +220,000 New
ECM
16
Endurant Capital Management
California
$1.16M +$1M +178,461 New
NA
17
Nottingham Advisors
New York
$957K – – –
BCM
18
Bridgeway Capital Management
Texas
$672K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$541K +$77.1K +13,699 +20%
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$533K -$8.49K -1,509 -2%
HP
21
Hikari Power
Japan
$521K – – –
TCIM
22
TIAA CREF Investment Management
New York
$463K +$105K +18,736 +36%
PPA
23
Parametric Portfolio Associates
Washington
$400K +$138K +24,576 +67%
Charles Schwab
24
Charles Schwab
California
$349K +$85K +15,100 +39%
AllianceBernstein
25
AllianceBernstein
Tennessee
$289K – – –
1
2 3 4

OCUL Hedge Fund Activity: Q1 2018 in Review

65 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2018, worth a combined $140M — up 133% from $60.1M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of OCUL and 7 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 25 added.

The largest buyer was Summer Road, opening a new position worth an estimated $17M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $277K sold.

  • 65 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2018, down from 69 in Q4 2017.
  • Funds reported $140M of Ocular Therapeutix stock for Q1 2018, up 133% quarter-over-quarter.
  • 7 funds opened new Ocular Therapeutix positions in Q1 2018 and 11 closed out, a net change of -4 holders.
  • The largest Ocular Therapeutix buyer in Q1 2018 was Summer Road, an estimated $17M added.
  • The largest Ocular Therapeutix seller in Q1 2018 was Susquehanna International Group, an estimated $277K sold.

Based on aggregated 13F filings for Q1 2018.